SSamsung Biologics Read More Samsung Biologics Wins End-to-End Big Pharma DealsAugust 14, 2026 Samsung Biologics (207940.KS) will handle contract manufacturing (CMO) of “zumilokibart,” a new drug candidate developed by global pharmaceutical…
SSamsung Biologics Read More Samsung Biologics Wins End-to-End Big Pharma DealsAugust 13, 2026 Samsung Biologics (207940.KS) will handle contract manufacturing (CMO) of “zumilokibart,” a new drug candidate developed by global pharmaceutical…